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SUPPLEMENTARY RESULTS
Generation of the xE and xM cell populations.
For these studies we used the well-characterized human mammary epithelial (HME) cell culture model, involving human mammary epithelial cells immortalized by forced expression of hTERT (1, 2) . We proceeded to transform these cells by introduction of SV40 early-region genes and the HRAS V12 oncogene, resulting in HMLER cells (1) , and labelled them for easy detection with either Clover or tdTomato reporters, both membranebound fluorescent proteins, (3, 4) . In order to enrich for tumor cell populations with differing epithelial (E) versus mesenchymal (M) traits, we initially FACS-sorted HMLER cells using the frequently employed CD24/CD44 cell-surface markers into epithelial (E) CD24 hi CD44 low (HMLER44L) and more mesenchymal (M) CD24 low CD44 hi (HMLER44H) populations (Supp. Fig. 1A ) (5, 6) . We then further stratified the heterogeneous HMLER44H cells using the marker CD104, as described recently (7) , in order to generate both a CD104 + CD44 hi population of hybrid epithelial-mesenchymal (E/M) phenotype and a more mesenchymal (M) CD104 -CD44 hi cell population. Importantly, this particular M population remained capable of regenerating substantial numbers of more epithelial CD104+ cells over extended periods of passaging time in vitro, which eventually represented ~30% of the overall cell population (Supp. Fig. 1B ). Because of this ongoing plasticity, we employed seven sequential rounds of FACS sorting in order to further enrich for more homogeneous cell subpopulations, which resulted in the highly pure E (CD104 + CD44 low ), the E/M (CD104 + CD44 hi ) and xM (CD104 -CD44 hi ) tumor cell populations ( Fig. 1A of main text). Control experiments revealed that proliferation rates in monolayer culture of the cells in these three populations were not significantly different (Supp. Fig. 1 D) . Moreover, levels of the introduced RAS oncoprotein, as determined by western immunoblots, were comparable in the E and E/M cells and up to 2-fold elevated in the xM cells ( Fig. 1C of main text). As cited above, the parental, generally mesenchymal, more heterogeneous CD44/CD104derived M cell population from which we isolated the fully mesenchymal xM cells displayed a ~30% subpopulation of CD104 + E/M cells, relative to such a corresponding CD104 + subpopulation of only 5% in the xM cells ( Fig. 1A , Supp. Fig. 1B ). This raised the question of which specific property distinguished the xM and M cells from one another. In contrast to the xM tumors, M tumors weighed on average 0.55 g per tumor ( Fig. 2) , closely resembling in size the E/M tumors (~ 0.7 g) and were, by contrast, about 10-fold larger in size than the xM-derived tumors. This result indicated that the M cells exhibited a degree of phenotypic plasticity that enabled them to generate a significant CD104 + E/M subpopulation while the xM cells lacked this plasticity and thus an ability to generate such E/M cells. The ability to generate E/M cells, in turn, was apparently responsible for the relatively high tumor-forming and stem cell frequencies relative to the M cells, which was similar to that of the E/M cells and was confirmed by stem cell frequency analysis conducted by implantations at limiting dilutions (Supp. Fig. 1C ). Such behavior confronted us with two alternative mechanistic hypotheses: (i) that residence in the E/M state, independent of plasticity, was important for stemness or (ii) that plasticity and an ability to move into and out of the E/M state was critically important for display of this trait. To determine whether cell plasticity played a critical role in the elevated tumor-initiating and outgrowth capabilities of M cells relative to those of the xM cells, we performed FACS analysis using the cell-surface CD44 and CD104 markers of the cells prepared from individual tumors. Prior to injection, the majority of M and xM cells (70% and 95%, respectively) resided in a predominantly CD104state. To gauge the degree of plasticity exhibited by these cells while growing within tumors, we monitored the percentage of cells that shifted from their initial more mesenchymal CD104state to a more epithelial CD104 + state. We found that both M cells and xM tumors, showed high degrees of plasticity in vivo with a high variability between individual tumors. Thus, 39% to 89% of the cells within the M-initiated tumors had gained epithelial properties and thus shifted into a CD104 + CD44 hi E/M state in vivo (Supp. Fig. 1F ). Similarly, 26-69% of xM cells shifted from an xM to a mixed E/M cell state as determined by their CD104/44 FACS profile (main Fig1 H, I). This revealed that, while the xM carcinoma cells generally resided stably in an xM state, those few cells that successfully grew out to form small tumors exhibited phenotypic plasticity as evidenced by their ability to generate E/M progeny. Taken together, these various observations suggested an association between the generation of subpopulations of E/M cells and acquisition of tumor-initiating ability. Indeed, this was compatible with the notion that residence in the E/M state was required for tumor-initiating ability and might even suffice, in the absence of plasticity, to generate tumor-initiating cells. As a corollary of this, we presumed that the observed tumorigenic powers of the more heterogeneous mesenchymal (M) cell population depended on their ability to generate E/M subpopulations, doing so in a way that depended on their intrinsic plasticity. As mentioned above, we note that the E cells bore only a minute subpopulation of tumorinitiating cells (Supp. Fig. 1C ). We reasoned that if residence in the E/M state was crucial to tumor-initiating ability, as argued immediately above, we should observe, in the few tumors seeded by the E cells, a shift toward an E/M state in vivo with associated gain of certain mesenchymal properties. Confirming results by Chaffer et al. (8) , we found that indeed 15% of the tumors generated by the implanted E cells expressed certain mesenchymal markers in vivo, as determined by CD44 marker analysis (main Fig. 1H , I, Supp. Fig. 1F ), compared to around 2% of CD44 hi E cells in vitro, suggesting additionally that gain of certain mesenchymal traits enabled concomitant acquisition of tumor-initiating properties (9, 10) .
Generation of xE Zeb1 KO cell lines
In order to trap cells entirely in an xE state, we used the CRISPR/Cas9 technology to completely eliminate Zeb1 expression in a population of E cells (Supp. Fig. 1A ). We began by comparing the ZEB1 CRISPR knockout (KO) cell clones and Zeb1-overexpressing clones with their respective isogenic controls, wishing also to exclude possible pre-existing genetic differences among the engineered single cell clones. To do so, we first isolated epithelial and mesenchymal single-cell clones (E-SCC and M-SCC, respectively) from the HMLER parental population. Furthermore, in order to minimize any cell-intrinsic disposition for plasticity, we screened E-SCC and M-SCC clones for those displaying the lowest level of plasticity as determined by either a gain of CD44 or CD104 marker expression, respectively (Supp. Fig. 2A ). Both epithelial and mesenchymal SCCs were then targeted with small guide (sgRNA) for ZEB1, subjected subsequently to single-cell cloning, and validated by sequencing of the appropriate DNA sequences, thereby generating the E-SCC-Zeb1KO or M-SCC-Zeb1KO cells (Supp. Fig. 2B -D). Mesenchymal cells were included in the targeting to function as controls, allowing us to calibrate the effectiveness of the ZEB1 CRISPR knockout. Zeb1 KO was validated by western blotting or IF staining. Because the E cells do not naturally express Zeb1, we induced an EMT in these cells by EMT-TF expression or treatment with TGF-β to validate the efficiency of the Zeb1KO (Supp. Fig. 2B , 3B, 5B, C). These E-SCC-Zeb1KO cells upon TGF-β did not express Zeb1 and were thus termed xE cells. As described in the main text, these cells progressed into an E/M state upon TGF-β treatment and were not able to complete the EMT process and move into an xM state (Supp. Fig. 3B, 5A ).
Zeb1 KO in xM cell lines
In light of our demonstration that Zeb1 was required for completion of the entire EMT program, we asked whether, conversely, Zeb1 loss in M cells would result in a mesenchymal-epithelial transition (MET). To this end, we examined M-Zeb1KO cells in vitro, in which ZEB1 had been knocked-out in fully mesenchymal M CD104 -CD44 hi cells. ZEB1 KO in the mesenchymal cells led to the reactivation of expression of the epithelial marker CD104, yielding cells that stably resided in a CD44 hi CD104 + E/M state as detected by CD104/CD44 marker analysis of xenografts. Moreover, these cells re-expressed the epithelial marker E-cadherin, which could be detected at low levels at the cell membrane by IF (Supp. Fig. 3D ). Similar to certain other E/M cell populations described here, the residence of these cells in this mixed E/M phenotype was stable with low plasticity maintained in vivo, as demonstrated by FACS analysis of digested tumors that had previously been growing in mammary fat pads (which revealed uniform expression of the CD104 + CD44 hi marker state in all the cells) (Supp. Fig. 3C ). Hence, loss of Zeb1 expression in these M cells led to a partial MET, with reversion of cells from a mesenchymal state to the hybrid E/M state, which once again displayed low plasticity along the E-to-M axis in vivo.
Canonical Wnt signaling in the E/M cells
To further test the hypothesis that the E/M cell population is marked by elevated canonical Wnt signaling, we transfected cells with the 7xTCF-GFP-reporter (7TGP), which acts as a transcriptional reporter of β-catenin-mediated canonical Wnt signaling (11) . Indeed, previous data in our lab suggested that canonical Wnt3a and TGF-β1 work synergistically to induce an EMT program (12) . To validate this reporter assay, we therefore overexpressed in these cells a strong canonical Wnt inducer, Wnt3a (Supp. Fig. 6C ). We then undertook to monitor canonical Wnt signaling as cells passed progressively through various E -M states (E, E/M, xM) by treating these E-7TGP-Wnt3A-expressing cells with TGF-β1. Interestingly, we observed that GFP induction was observed in E cells and was twice as high in the E/M cell populations; however, the levels of GFP + cells were 5-fold lower in the xM cells compared to E/M cells (Supp. Fig. 6D-F) . These observations confirmed that canonical Wnt signaling was highly active in E/M cells as accounted for by a strong GFP signal, but was downregulated as cells moved into an xM state.
Canonical Wnt signaling and Snail are both negatively regulated by GSK-3β (13, 14) . Using the GSK-3β inhibitor BIO (6-bromoindirubin-3'-oxime) (15) on E cells expressing Wnt3a and the canonical Wnt signaling reporter 7TCF-GFP, we could validate in HMLER cells that inhibition of GSK-3β did indeed lead to an increase in the percentage of GFP+ cells and canonical Wnt signaling (Supp. Fig. 6G ). Moreover, we found that GSK-3β inhibition induced an EMT in the HMLER-E cells, as measured by CD104/CD44 marker expression by FACS, similar to an induction by EMT-TFs such as Snail or Zeb1, which drive cells into the CD44 hi state (Supp. Fig. 6G ). These combined findings are consistent with the notion that the shift from an E to an E/M state could be driven by stabilizing canonical autocrine Wnt signaling. The alliance between β-catenin and Snail is underscored by the fact that both are downregulated by GSK-3β (14, 16, 17) . Hence, it is not surprising that by blocking GSK-3β using the GSK-3β inhibitor BIO (6-bromoindirubin-3'-oxime) (15), we could not only induce canonical Wnt signaling (Supp. Fig. 6G ) but also elicit a partial EMT in the epithelial HMLER cells.
SUPPLEMENTARY MATERIALS AND METHODS
Cell lines and culture conditions
HMLER cells were cultured in 500 ml MEGM media (Lonza Bullet kit), supplemented with 250 ml DME, 250 ml F12, insulin (10µg/ml), EGF (10 ng/ml), hydrocortisone (1µg/ml), 1x Pen/Strep. SUM149 cell lines were cultured in F12 with 5% inactivated calf serum (IFS), 1ug/ml hydrocortisone, insulin (5ug/ml), and pen/strep. All cell lines were passaged every two to three days to keep cells in sub-confluent conditions. If stated cells were treated with BIO (6-bromoindirubin-3'-oxime) compound (Sigma) at a concentration of 1:20.000. Media was exchanged every two days.
Plasmid constructs and virus construction HME (1) cells were transformed with pENTR1A SV40 LgT (Addgene 22297) cloned into pLenti CMV Neo DEST and pWZL-HRASg12v-Blast (18) . To color-code cells, pLV-tdTomato-membrane was used and pLV-YFP-membrane (19) was subcloned and substituted with Clover (3) using the amplification primers (CTGGACGGCGACGTGAAC/ GCCCATATGCCTTACTTGTAC) into the BmgBI/NdeI site, creating pLV-Clover-membrane; and eBFP2 synthesized by IDT, creating pLV-EBFP-membrane. pLenti-CRISPR-Cas9 V2 (Addgene 52961) constructs were produced as previously described (20) . Spacer guide sequences used for the constructs were: sgZEB1 (GAGCACTTAAGAATTCACAG) sgSNAIL (GGGACTCTCCTGGAGCCGAA); non-cutting controls sgNC (ACGGAGGCTAAGCGTCGCAA) (kindly provided by Yun Zhang, Whitehead Institute for Biomedical Research, Cambridge, MA). For SNAIL, TWIST and SLUG overexpression pLV IRES Tom expression vector was used (kindly provided by Leonardo Rodriguez, Whitehead Institute for Biomedical Research, Cambridge, MA). ZEB1 overexpression was induced using a pLenti CMV Puro DEST (w118-1) gateway recombined (LR) with ZEB1 V2 from Genecopoeia (GC-F0876-B, Addgene 17452). Blast resistance sequence was substituted in pLenti CMV Blast DEST with EBFP-membrane or tdTomatomembrane creating pLenti CMV tdTomM DEST and pLenti CMV EBFPM DEST. The pLV EBFP Zebmt was constructed exchanging the sgRNA targeting sequence within, with a gene fragment containing the substitute sequence GAACATTTGAGGATACATAG in the Zeb1 vector described above and then subloned into pLenti CMV EBFPM DEST. Fzd8-CRD (21) was subloned into pENTR1A using EcoRI/ApaI into EcoRI/EcoRV restriction side, respectively and further subloned into the Dox inducible gateway expression vector pCW57.1, a gift from David Root (Addgene 41393). Active Wnt3A-V5 (Addgene 43810), Active Wnt5A-V5 (Addgene 43813), Active Wnt7A-V5 (Addgene 43816), Active Wnt7B-V5 (Addgene 43817) (22) were subcloned into pENTR1A and further subcloned into pLenti CMV tdTomM DEST. 7TGP was a gift from Roel Nusse (Addgene 24305). pLenti-based constructs were packaged with pMD2.G (VSVG) and psPAX2 plasmids (Addgene 12259 and 12260, respectively). H-Ras V12 blast was packaged with pUMVC (Addgene 8449) and pMD2.G. Viral infections were performed using 5 µg/ml Polybren (EMD Millipore) for 16 h.
Generation of CRISPR/Cas9 HMLER KO and overexpression clones
To compare CRISPR clones to isogenic controls, single-cell clones (SCCs) were isolated from E and M populations. In brief, single-cells that had been sorted by FACS were seeded into 96-well plates and 24 SCCs were grown up. Clones were selected after FACS CD104/CD44 marker analysis, namely clone M-SSC #12 and E-SCC #5. CRIPSR targeting with sgRNAs for Zeb1 or Snail were performed (Supp. Fig. 2B ). Out of 3 different sgRNAs tested, the most efficient was chosen for subsequent experiments. Homozygous frame-shift mutations in the genomic region targeted by the CRISPR-Cas9 construct were confirmed by sequencing using the following sequencing primers: Zeb1 (CAAAACAACCATCAGGCTCA/ TTCCATTCCCCTGCTAATTG) Snail (ATTGAGAATCGGCCCCACC/ CCAAACGTTTCCAGAGAGCC). Clones were analyzed for CRISPR/Cas9 levels (determined by FLAG expression) and similar tumorigenic potential. To exclude sub-clone specific results clones were analyzed first individually and then 3 were pooled in equal ratios (Supp. Fig. 2 C and D) . In similar fashion over-expression cell clones were generated in M-SCC cells using pLVX Zeb1.
Quantitative Real-Time-PCR and Primers and RNA-Seq
Q-PCR and RNA-Seq. were performed as described before (7) . In brief total RNA was isolated using TRIzol followed by RNeasy Micro Kits (Quiagen). Reverse transcription was performed with cDNA Synthesis Kits, including RNAse Inhibitor (Applied Biosystems). Quantitative RT-PCR was performed using a Roche Diagnostics LightCycler 480 II and SYBR Green Mastermix (Roche). Primers used for analysis: Krt5 (CAGCCGGAGCCTCTACAACC/ CGCCGAAACCAAATCCACTAC), Krt8 (GATGCTGGAGACCAAGTGGAG/ GCCGCCTAAGGTTGTTGATG); E-Cad (TTGCACCGGTCGACAAAGGAC/ TGGATTCCAGAAACGGAGGCC), Zeb1 (GATGATGAATGCGAGTCAGATGC/ ACAGCAGTGTCTTGTTGTTGT), Slug (TACCGCTGCTCCATTCCACG/ CATGGGGGTCTGAAAGCTTGG), Snail (TCGGAAGCCTAACTACAGCGA/ AGATGAGCATTGGCAGCGAG), GAPDH (GTCTCCTCTGACTTCAACAGCG/ ACCACCCTGTTGCTGTAGCCAA).
Nuclear fractionation and western blotting
Western blotting was performed as follows: Cells were washed in PBS and total protein was extracted in RIPA buffer (Invitrogen) supplemented with Phosphatase Inhibitors (mixture 2 and 3, Sigma) and Complete Protease Inhibitors (Roche) for 30 min on ice. For nuclear fractionations cells were scraped off in ice-cold PBS and pelleted at 1000 g for 3 min. Cells were re-suspended by pipetting and lysed in Nuclear lysis buffer (5 mM PIPES (pH8.0), 85 mM KCl, 0.5% NP40, supplemented with protease and phosphatase inhibitors as stated above) for 10 min on ice. Lysates were microfuged at 2300 g for 5 min at 4°C to pellet nuclei. Supernatant was collected as cytoplasmic fraction. Nuclear pellets were lysed using RIPA buffer as stated above. All protein lysates were microfuged at 13,000 g for 30 min at 4°C before total protein was determined by the BioRad protein quantification kit. Samples were prepared and western blot performed according to manufacturer's instructions (Thermo Fisher Scientific). Separation of total protein extracts was carried out in 1xMOPS buffer using NuPAGE Novex 4-12% Bis-Tris gels. Proteins were electrotransferred to PVDF membrane by wet blotting in NuPAGE Transfer buffer. Blocking and antibody incubations were performed as described by CST. Secondary antibodies (CST) were used at 1:10,000 dilution detected with Pierce Femto or Dura ECL (Thermo Fisher Scientific) as substrate
Immunofluorescence and histology analysis
Immunofluorescence analysis on cells and tissues were performed as described before (23, 24) . Sterilized coverslips were placed directly into culture dishes. For keratin staining, cells were fixed for 5 min in -20°C methanol, 30 s in -20°C acetone, otherwise cells were fixed for 15 min in 4% formalin/PBS at 4°C, washed in TBS, and then permeabilized for 5 min in 0.25% Triton/TBS. After a TBS wash, they were incubated for 1 h or overnight at 4°C with primary antibodies diluted in TBS/1% BSA. Secondary antibodies at 1:400 dilutions were applied and incubated for 30-60 min. Nuclei were counterstained using 1:1,000 diluted DAPI. Coverslips were mounted with Prolong Gold (Invitrogen). For histology, tissues were fixed overnight at 4°C in 4% formalin, sequentially incubated at 4°C overnight in 15% and 30% sucrose, embedded in paraffin, and sectioned (5 μm). Antigens were retrieved with citrate buffer (18 mM citric acid monohydrate, 82 mM sodium citrate, pH 6.0) and the antibodies were diluted in TBS containing 1% BSA and 5% NGS. For Zeb1 staining on tissues an amplification step using the TSA Plus Kit (PerkinElmer) was performed according to manufactures instructions. Slides were mounted in ProLong Gold antifade reagent (Invitrogen).
Immunofluorescence microscopy and data processing. H&E images were acquired using an Axioskop microscope with a Plan Neofluar 10x /0.30 Ph1 objective using an AxioCam 105 color (Zeiss) and fluorescent images were obtained using an Observer.Z1with an ApoTome2 (Zeiss) microscope with Apochromat 20x/ 0.8 M27 or 63x /1.4 oil immersion objectives at room temperature using an AxioCam506 (Zeiss). Image analysis and processing were performed using the Zen2 (Zeiss) and Adobe PhotoShop CC2017 software. LUT (brightness and gamma) was adjusted using Adobe Photoshop. 
